No Data
No Data
Jinling Pharmaceutical (000919.SZ): Its subsidiary, Ipratropium Bromide, has obtained a notice of approval for the marketing application of chemical raw materials.
On June 28, Gelunhui reported that Jinling Pharmaceutical (000919.SZ) recently announced that its subsidiary, Chizhou Dongsheng Pharmaceutical Co., Ltd. (hereinafter referred to as 'Dongsheng Pharmaceutical'), controlled by Jinling Pharmaceutical Co., Ltd., received the 'Chemical Active Pharmaceutical Ingredient Market Approval Notice' (Notice No. 2024YS00595) issued by the State Drug Administration for its ingredient of ipratropium bromide. Ipratropium bromide is used to relieve bronchospasm and asthma symptoms caused by chronic obstructive pulmonary disease (COPD), and is suitable for the prevention and treatment of asthma, especially for those who cannot tolerate such drugs due to the side effects of beta receptor agonists, such as muscle tremors and tachycardia.
Jinling Pharmaceutical (000919.SZ): As of June 20, 2024, the total number of shareholders of the company is 36,441.
Jinling Pharmaceutical (000919.SZ) stated on the investor interaction platform on June 26 that as of June 20, 2024, there were 36,441 shareholders in the company.
Jinling Pharmaceutical (000919.SZ) 2023 equity distribution: 1 yuan for every 10 shares
Jinling Pharmaceutical (000919.SZ) issued an announcement. The company's 2023 equity distribution plan is: With the company's current...
Jinling Pharmaceutical (000919.SZ): As of May 10, 2024, the total number of shareholders of the company was 37,991
Gelonghui May 14 | Jinling Pharmaceutical (000919.SZ) said on the investor interactive platform that as of May 10, 2024, the total number of shareholders of the company was 37,991.
Jinling Pharmaceutical (000919.SZ): Currently, major products have not entered national collection
Gelonghui May 9丨Jinling Pharmaceutical (000919.SZ) held a performance briefing on May 9, 2024 to “ask which varieties of the company may enter collection in the future?” The company replied that at present, the company's main products have not been collected by the country. The company will pay close attention to national collection policy trends and proactively respond to possible policy changes.
Why Jinling Pharmaceutical's (SZSE:000919) Shaky Earnings Are Just The Beginning Of Its Problems
No Data